NewsOK Local Stocks
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Cara Therapeutics (NQ: CARA)
25.34 USD  -0.52 (-2.01%)
Streaming Delayed Price  /  Updated: 10:18 AM EDT, Jul 23, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 140,763
Open 25.76
Bid (Size) 25.33 (1)
Ask (Size) 25.38 (8)
Prev. Close 25.86
Today's Range 25.30 - 25.80
52wk Range 12.19 - 27.55
Shares Outstanding 33,874,770
Dividend Yield N/A
Performance
YTD
+74.04%
+74.04%
1 Month
+25.45%
+25.45%
3 Month
+43.16%
+43.16%
6 Month
+65.19%
+65.19%
1 Year
+31.30%
+31.30%
Top News
More News
Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral... Read More
from GlobeNewswire News Releases
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis
Oral KORSUVA is now the subject of three separate, ongoing Phase 2 clinical trials Read More
from PR Newswire
More News
Read More
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis
from GlobeNewswire News Releases
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Second Pruritus Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™
from PR Newswire
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)
from GlobeNewswire News Releases
Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference
from GlobeNewswire News Releases
Cara Therapeutic Up 25.3% Since SmarTrend Uptrend Call (CARA)
from Comtex SmarTrend® News Briefs
Notable Friday Option Activity: CARA, ABMD, CBLK
category Stocks
from Market News Video
TUSA's Holdings Could Mean 11% Gain Potential
category ETFs
from ETF Channel
Cara Therapeutics Shows Market Leadership With Jump To 94 RS Rating
from Investor's Business Daily
3 Top Biotech Stocks to Buy for the 2nd Half of 2019
category CARA , VRTX , ALXN , and 1 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.